Moxonidine in the treatment of chronic kidney disease associated with hypertension

Y. Dombrovsky

Abstract


Kidney disease pathogenesis is closely related to essential or secondary hypertension. Treatment of chronic kidney disease associated with hypertension requires a comprehensive causal and pathogenetic therapy. The topic of the article is devoted to comparative characteristics of drugs used to treat patients with this pathology. The bulk of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using moxonidine, I1-imidazoline receptors agonist.


Keywords


hypertension; chronic kidney disease; I1-imidazoline receptors agonists; moxonidine

References


Eleni F. Karlafti, Apostolos I. Hatzitolios, Anastasios F. Karlaftis, Maria S. Baltatzi, Georgios G. Koliakos, Christos G. Savopoulos. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection // J. Pharm. Bioallied Sci. — 2013 Oct-Dec. — 5(4). — 253-256.

Fenton C., Keating G.M., Lyseng-Williamson K.A. Moxonidine: A review of its use in essential hypertension // Drugs. — 2006. — 66. — 477-96.

Prichard B.N., Owens C.V., Graham B.R. Pharmacology and clinical use of moxonidine, anew centrally acting sympatholytic antihypertensive agent // J. Hum. Hypertens. — 1997. — 11 (Suppl. 1). — S29-45.

Sica D.A. Centrally acting antihypertensive agents: An update // J. Clin. Hypertens. — 2007. — 9. — 399-405.

Fenton C., Keating G.M., Lyseng-Williamson K.A. Moxonidine: a review of its use in essential hypertension // Drugs. — 2006. — 66(4). — 477-96.

Edwards L.P., Brown-Bryan T.A., McLean L., Ernsberger P. Pharmacological properties of the central antihypertensive agent, moxonidine // Cardiovasc. Ther. — 2012 Aug. — 30(4). — 199-208.

Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension // J. Hypertens. — 2007. — 25. — 1751-62.

Mitrovic V., Hamel M., Miric M., Thormann J., Hamm C. Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertention. Effects of moxonidine on coronary circulation // Z. Kardiol. — 2001. — 90. — 953-63.

Van Kerckhoven R., van Veen T.A., Boomsma F., Saxana P.R., Schoemaker R.G. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model // Eur. J. Pharmacol. — 2000. — 397. — 113-20.

Poisson D., Christen M.O., Sannajust F. Protective effects of I (1)-antihypertensive agent moxonidine against neurogenic cardiac arrhythmias in halothane-anesthetized rabbits // J. Pharmacol. Exp. Ther. — 2000. — 293. — 929-38.

Sharma A.M., Wagner T., Marsalek P. Moxonidine in the treatment of overweight and obese patients with metabolic syndrome: A postmarketing surveillance study // J. Hum. Hypertens. — 2004. — 18. — 669-75.

Keulen L., Henricksen E.J., Jacob S., Lang R. Antihypertensive treatment and cardiovascular risk management in patients with the metabolic syndrome — focus on SNS and insulin resistance // J. Clin. Basic Cardiol. — 2001. — 3. — 193-5.

Krespi P.G., Makris T.K., Hatzizaxarias A.N., Triposkiadis P., Tsoukala C., Kyriaki D. et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension // Cardiovasc. Drugs Ther. — 1998. — 12. — 463-7.

Littlewood K.J., Greiner W., Baum D., Zoellner Y. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: A cost-effectiveness analysis // BMC Nephrol. — 2007. — 8. — 9.

Sagarad S.V., Biradar-Kerure S., Mr R., Kumar S.C., Reddy S.S. A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients — Prescription beyond Current Guidelines // J. Clin. Diagn. Res. — 2013 Oct. — 7(10). — 2213-5.

Deftereos S., Giannopoulos G., Kossyvakis C., Efremidis M., Panagopoulou V., Raisakis K., Kaoukis A., Karageorgiou S., Bouras G., Katsivas A., Pyrgakis V., Stefanadis C. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients // Am. J. Cardiol. — 2013, Sep 1. — 112(5). — 684-7.

Chazova I., Schlaich M.P. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study // Int. J. Hypertens. — 2013. — 2013. — 541689.

Amann K., Nichols C., Tornig J., Schwarz U., Zeier M., Mall G., Ritz E. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure // Nephrol. Dial. Transplant. — 1996 Jun. — 11(6). — 1003-11.

Benedict C.R., Francis G.S., Shelton B., Johnstone D.E., Kubo S.H., Kirlin P. et al. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators // Am. J. Cardiol. — 1995. — 75. — 1151-7.

Melo L.G., Veress A.T., Ackermann U., Steinhelper M.E., Pang S.C., Tse Y. et al. Chronic regulation of arterial blood pressure in ANP transgenic and knockout mice: Role of cardiovascular sympathetic tone // Cardiovasc. Res. — 1999. — 43. — 437-44.

Mobini R., Fu M., Jansson P.A., Bergh C.H., Scharin Täng M., Waagstein F. et al. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: Acute effects of the imidazoline I1 receptor agonist moxonidine // Clin. Sci. — 2006. — 110. — 329-36.

Dickstein K., Manhenke C., Aarsland T., McNay J., Wiltse C., Wright T. The effect of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure // Int. J. Cardiol. — 2000. — 75. — 167-76.

Swedberg K., Bristow M.R., Cohn J.N., Dargie H., Straub M., Wiltse C. et al. Effects of substained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure // Circulation. — 2002. — 105. — 1797-803.

Іванов Д.Д., Корж О.М. Нефрологія в практиці сімейного лікаря. — Донецк: Видавець Заславський O.Ю., 2014. — 464 с.




DOI: https://doi.org/10.22141/2307-1257.0.2.08.2014.76354

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru